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COMPLICATIONS OF 
EXTRACORPOREAL LIFE 
SUPPORT SYSTEMS USING 
HEPARIN-BOUND SURFACES 
The risk of intracardiac 
clot formation 
Extracorporeal ife support with heparin-coated extracorporeal membrane 
oxygenation circuits are being used with increased frequency in patients 
who have cardiogenic shock. We report our experience in 30 patients with 
cardiogenic shock, looking specifically at the complications associated with 
this form of life support. Thirty patients with a mean age of 46.5 -+ 16.6 
years received extracorporeal life support for a mean of 62.8 -+ 41.1 hours 
(range 0.5 to 159 hours). Twenty-three patients had postcardiotomy car- 
diogenic shock, five had acute myocardial infarction, and one each had 
acute cardiac deterioration after a balloon coronary angioplasty and 
another after pulmonary artery balloon angioplasty. Peripheral (femoral 
vein to femoral artery) cannulation was used in 24 patients. Limb ischemia 
developed in 21 patients (70%), renal failure in 17 patients (57%), 
oxygenator failure requiring change in 13 patients (43%), bleeding requir- 
ing reexploration in 12 (40%), and infection in 9 patients (30%). Trans- 
esophageal echocardiography revealed intracardiac thrombus formation in 
6 patients (20%) and clot was visualized grossly in the pump head in 2 
patients (6%) necessitating pump-head change. Nine patients (30%) were 
discharged home. We conclude that the use of heparin-coated extracorpo- 
real life support without systemic heparinization, especially after prota- 
mine has been used to reverse systemic heparinization in patients having 
postcardiotomy cardiogenic shock, may be dangerous. Extracorporeal ife 
support has introduced new complications unique to itself specifically limb 
ischemia, oxygenator failure, and pump-head thrombus. (J TnORAC CAR- 
DIOVASC SURG 1995;110:843-51) 
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E xtracorporeal life support with an extracorporeal membrane oxygenation (ECMO) circuit is being 
used more frequently to support adult patients who 
have cardiogenic shock 1' 2 and has been shown to 
provide excellent oxygenation and hemodynamic 
support. 1-3 Binding heparin to the extracorporeal 
circuit provides a more biocompatible surface, min- 
imizing early surface-induced complement activa- 
tion and platelet dysfunction, which may improve 
patient survival. 4 Moreover, the heparin-coated sur- 
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face has been proported, in experimental nd clini- 
cal reports, to obviate the need for systemic hepa- 
rinization. The absence of heparin may reduce 
bleeding problems, 5'6 especially in patients who 
have postcardiotomy cardiogenic shock. Superb 
clinical results have been recorded with heparin- 
bound extracorporeal life support circuits without 
systemic heparinization. 3 Nonetheless, the safety of 
avoiding systemic heparinization when blood is al- 
lowed to circulate outside the body despite a hepa- 
rin-coated extracorporeal circuit has been ques- 
tioned 7, 8 because thrombin is activated. This report 
demonstrates that thrombus formation within the 
heart and in the ECMO circuit is a potential hazard 
of foregoing heparin administration i patients up- 
ported by extracorporeal devices having heparin- 
bound surfaces. We report our experience with 30 
patients treated with extracorporeal life support for 
cardiogenic shock, looking specifically at the com- 
plications associated with the technique. 
843 
8 4 4 Muehrcke t aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1995 
Table I. Causes of cardiogenic shock and 
procedures performed 
Pts 
Postinfarction cardiogenic shock 5 
Postcardiotomy cardiogenic shock 23 
Heart transplantation 4 
Redo CABG 4 
CABG 4 
Pulmonary artery reconstruction 2 
Postinfarcfion VSD/CABG 2 
Redo CABG/MV repair 1 
Redo CABG/AVR 1 
AVR/MVR 1 
Septal myectomy 1 
Aortic autograft (Ross) 1 
Aortic homograft/MV repair 1 
Descending aortic aneurysmectomy 1 
Failed angioplasty 2 
Pulmonary artery dilatation (angioplasty) 1 
Acute myocardial infarction 1 
CABG, Coronary arteiy bypass grafting; VSD, ventricular septal defect; 
MV, mitral valve; AVR, aortic valve replacement; MVR, mitral valve 
replacement. 
Patients and methods 
During the 22-month period between September 1992 
and July 1994, 30 patients in eardiogenic shock wcre 
treated with a venoarterial extraeorporeal life support 
system that had heparin-bound tubing (Carmeda, 
Medtronics, Inc., Minneapolis, Minn.). The criterion to 
use ECMO for cardiac support was the inability to treat 
shock adequately by means of conventional methods of 
support. The largest group of patients (n = 23) had 
posteardiotomy cardiogenic shock. These patients re- 
mained in shock despite an anatomically correet surgical 
procedure, after all metabolie, rhythm, and respiratory 
abnormalities had been corrected. The patients eould not 
be weaned from bypass despite high doses of at least two 
inotropic agents (usually after intraaortic balloon pump 
[IABP] placement). Although the age of the patients was 
taken into consideration, emergency cases were not ex- 
cluded. This group represented 0.38% of all patients 
undergoing eardiac operations during this time interval at 
The Cleveland Clinic. Seven patients, including five hav- 
ing postinfarction cardiac shock and two having shock 
after unsuccessful angioplasty, were treated with ECMO 
after all attempts at stabilization failed to produce an 
adequate cardiac output in the eardiac catheterization 
laboratory. All patients were receiving high-dose inotropic 
support and six of the seven had an IABP inserted. Table 
I describes the causes of cardiogenic shock and proce- 
dures performed. The hospital records, extracorporeal life 
ùsupport records, cardiopulmonary bypass records, and 
blood transfusion records of each patient were retrospec- 
tively reviewed. Additionally, transesophageal echocar- 
diographic stndies before and during extracorporeal life 
support were evaluated for the presence of intracardiac 
clot formation, spontaneous contrast (representing stag- 
nant blood flow), and left ventricular dilatation (left 
ventricular end-diastolic diameter greater than 6 cm). 
Table I I . Method of cannulation for extracorporeal 
life support 
No. of 
patients 
Femoral vein to fernoral artery (percutaneous) 24 
Right atrium to ascending aorta (open chest) 5 
Femoral vein to ascending aorta (open chest) 1 
Complications including intracardiac clot formation, 
stroke, oxygenator failure, pump-head failure, infection, 
need for reexploration for bleeding, limb ischemia (limb 
discoloration, coolness to touch, or loss of sensation), 
need for hemodialysis or ultrafiltration, and blood trans- 
fusions were recorded. Results were computed for pa- 
tients as a whole. Complications were analyzed with 
respect o age, mode of cannulation, duration of cardio- 
pulmonary bypass for patients having postcardiotomy 
cardiogenic shock, length of time receiving extracorporeal 
life support, height, weight, body surface area, time when 
support was initiated (intraoperative, postoperative, in the 
catheterization laboratory), use of an IABP, use of sys- 
temic heparinization, and average pump flows. Univariate 
logistic regression analysis of these parameters was per- 
formed to identify clinical predictors of intracardiac clot 
formation, ability to be weaned, and death. 
The ECMO circuit was composed of a hollow-fiber, 
microporous membrane oxygenator (Maxima, Medtron- 
ics) and heat exchanger (Cincinnati Sub Zero, Cincinnati, 
Ohio), an oxygenator blender (Sechrist Industries, Inc., 
Anaheim, Calif.), and an arteriovenous loop made from 
standard 3/s-inch Tygon tubing (Norton Performance Plas- 
tics, Wayne, NJ.). A centrifugal biopump (Medtronics) 
was used. All components of the system with blood 
contact were heparin coated (Carmeda BioActive Sur- 
face), as were all eannulas. Wire-wound heparin-coated 
(Carmeda) arterial and venous cannulas were used for 
arterial return ffom the ECMO cireuit and for venous 
drainage, respectively (Medtronics). Arterial cannula 
sizes varied from 17F to 21F and venous cannulas ranged 
from 18F to 20F. The decision to cannulate the femoral 
vessels (which were preferred) or the mediastinal great 
vessels was based on the size of the femoral artery and the 
amount of venous return. If the femoral artery was too 
small to accept the smallest arterial cannula or if the 
patient had peripheral vascular disease, then the aorta was 
used for blood return from the ECMO circuit. If the 
venous return was poor or the aorta had to be used for 
blood return from the ECMO circuit, then the right 
atrium was cannulated. Patients were treated according to 
the surgeon's preference, and six surgeons and four 
cardiologists were responsible for initial ECMO cannula- 
tion. We did not use distal leg perfusion. 
Table II describes the method of cmmulation for extra- 
corporeal ife support. The majority of cannulas were 
inserted via the femoral vein and femoral artery. In 24 
patients the ECMO cannulas were placed percutaneously. 
These 24 include 17 patients with posteardiotomy cardio- 
genic shock, in all of whom the mediastinal incisions were 
closed to help control bleeding and prevent infection. In 
six other patients having postcardiotomy cärdiogenic 
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shock, the ascending aorta was cannulated and the sternal 
incisions were not closed. In total, we managed six pa- 
tients by not closing the mediastinal incision. The femoral 
artery and vein were used in all patients in whom percu- 
taneous ECMO was initiated in the catheterization labo- 
ratory. Patients with signs of tamponade or persistent 
excessive mediastinal hemorrhage despite correction of 
clotting factors (prothrombin time, partial thromboplastin 
time, activated clotting time, and platelet count) had an 
exploratory operation either in the intensive care unit if 
the chest had been left open or in the operating room if 
the sternotomy incision had been elosed completely. 
Twenty-three patients had an IABP inserted before extra- 
corporeal life support was begun. The IABP was used in 
an effort to decrease afterload, as deseribed by Lazar and 
associates. 9 The seven patients not treated with IABP 
support included four patients in whom ECMO was 
initiated in the postoperative p riod in the intensive are 
unit (14 to 77 hours after the operation), two pediatric 
patients, and one patient with postcardiotomy cardiogenic 
shock in whom the surgeon chose not to use it. Systemic 
heparinization was used in only five patients (average dose 
700 units/hr) because of the surgeon's concern for not 
using systemic heparin with the ECMO circuit. Average 
pump flows during extracorporeal life support were 
3.75 _+ 1.05 [,/min (range 1.1 to 5.8 L/min). 
Transesophageal echocardiography was routinely per- 
formed in all patients at multiple times during the extra- 
corporeal life support period. Furthermore, transesopha- 
geal echocardiography was used during attempts to wean 
patients from the life support circuit. Patients with intra- 
cardiac thrornbus formation were managed by having the 
clot removed (n = 3) surgically or, if this was believed too 
dangerous, ystemic heparinization was begun (n = 3). 
In patients treated with extracorporeal life support for 
postcardiotomy cardiogenic shock, systemic hepariniza- 
tion was reversed with protamine during the operation 
after the ECMO circuit was in place and running. Patients 
in whom lee support was begun in the cardiac catheter- 
ization laboratory or after the operation in the intensive 
eare unit were given 5000 units of heparin at the time of 
insertion of the life support circuit and no protamine was 
given. All patients received 5000 units of heparin intrave- 
nously during periods of low flow or pump stasis (i.e., 
changing of an oxygenator pump head). Similarly, 5000 
units of heparin was given during periods of weaning from 
the life support circuit. Heparin was otherwise not rou- 
tinely continued uring support, except in five patients. In 
the five patients receiving intravenous heparin, aetivated 
clotting times were kept greater than 200 seconds. Other- 
wise activated clotting times were not measured routinely. 
Epsilonaminoeaproic aeid (Amicar) was used in six pa- 
tients undergoing a second cardiac operation. Aprotinin 
was not used in any patient. Bleeding was treated by 
transfusion of packed red blood eells, fresh-frozen plasma, 
platelets, and cryoprecipitate when necessary. Left ven- 
tricular selective decompression was not used. During 
ECMO, the patients were weaned from inotropic agents if 
possible (except renal dose dopamine) to prevent further 
myocardial ischemia. No effort beyond IABP use was 
made to ensu:re that pulsatile flow was maintained. 
With the aid of a transesophageal chocardiogram to 
visually inspect he heart, weaning attempts were made 
when cardiac recovery was evident after 24 hours of 
assistance. Pump flow was gradually reduced as cardiac 
function was determined with transesophageal chocardi- 
ography. If good ventricular ejection was maintained 
while the patient was being weaned from the ECMO and 
a native cardiac index of 2.2 L/min per square meter could 
be maintained, extracorporeal life support was discontin- 
ued. Nine patients who were believed to have irreversible 
left ventricular dysfunction and who otherwise were can- 
didates for cardiac transplantation were converted from 
the ECMO system to a more durable implantable left 
ventricular assist device (HeartMate, Thermo Cardiosys- 
tems, Inc., Woburn, Mass.). These patients were less than 
65 years old, had not demonstrated adequate improve- 
ment in left ventricular function to allow weaning from the 
ECMO circuit, and were thought to have intact neurologic 
function. All patients were cleared for transplantation 
before receiving an implantable left ventricular assist 
device. 
Results are recorded as mean _+ standard eviation. 
Continuous variables were analyzed by Student's t test or 
the Wilcoxon two-sample t st. Fisher's exact est for 2 × 
2 tables was used for categoric variables. Analysis was 
considered statistically significant at the p < 0.05 level. 
Univariate logistic regression analyses were performed for 
the variables that converged and were significantly related 
(p ~ 0.05) to the outcomes. Multivariate analyses were 
not performed because of the small sample size. 
Results 
The average patient age was 46.5 _+ 16.6 years 
(range 5 to 70 years). Twenty-one were male. Two 
patients were younger than 19 years and two older 
than 70 years of age. The average duration of 
extracorporeal life support was 62.8 _ 42.1 hours 
(range 0.5 to 159 hours). In patients having postcar- 
diotomy cardiogenic shock, Cardiopulmonary b pass 
lasted an average of 225.3 _ 122.4 minutes (range 
87 to 626 minutes). Of the 23 patients having 
postcardiotomy cardiogenic shock, 15 received the 
ECMO in the operating room and nine during the 
postoperative period, an average of 70.8 ___ 103.9 
hours (range 12 to 122 hours) after the operation. 
Twelve of 23 patients having postcardiotomy cardio- 
genic shock required reexploration for bleeding, 
including six patients whose chests were left open. 
Nine patients received an implantable left ventricu- 
lar assist device (HeartMate) as a bridge to potential 
heart transplantation. Five of these patients had 
postinfarction cardiogenic shock and the other four 
had postcardiotomy cardiogenic shock. Two patients 
who had received a left ventricular assist device later 
required placement of a right ventricular assist 
device. One of these patients remained hypoxic 
despite the absence of a patent foramen ovale, and 
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an oxygenator was added to the assist device circuit. 
Five patients who received a left ventricular assist 
device subsequently had heart transplantation, and 
all were discharged home after 106 + 15 days of left 
ventricular assist device support (Table III). 
Complications. Complications develop fre- 
quently in patients receiving extracorporeal life sup- 
port (Table IV). Limb ischemia was the most com- 
mon complication and was found only in the 
patients cannulated percutaneously via the femoral 
artery. Although 21 patients (70%) had signs of 
ischemia (coolness, loss of sensation, or discolora- 
tion), only nine patients (30%) required thrombec- 
tomy and one an amputation. Renal dysfunction was 
also common. Over half of the patients (17) re- 
quired either dialysis (47%) or continuous veno- 
venous ultrafiltration (10%). Seven patients devel- 
oped infectious complications. Bacteremias (all 
gram-positive cocci) developed in six patients and 
mediastinitis (Staphylococcus epidermidis) in one. In 
all but one, bacteremia was transient and cleared 
with antibiotics and changing of central ines. In one 
case the bacteremia progressed to endocarditis (S. 
epidermidis) and was the cause of death in that 
patient. Oxygenator failure occurred in 13 patients. 
The mean number of oxygenator changes was 2.25 
+_ 1.0 (range 1 to 4) per patient in whom an 
oxygenator failed. The mean time to oxygenator 
failure was 41.7 +- 28.9 hours (fange 5 to 103 hours). 
Four patients required pump-head change, two be- 
cause clot was detected within the pump head and 
two prophylactically because of excessive noise and 
vibration of the pump potentially signaling pending 
pump failure. 
Table V demonstrates the significant results of 
transesophageal echocardiography while patients 
were receiving extracorporeal life support. Marked 
left ventricular distention developed in half the 
patients. In six patients, intracardiac clot was found 
to have developed uring extracorporeal life sup- 
port (see Table III). All had prior echocardiograms 
failing to identify thrombus. None of the patients in 
whom intracardiac lot developed uring extracor- 
poreal life support had received systemic hepa- 
rinization. Clot developed in the left atrium in two 
patients (both had indwelling left atrial pressure 
monitoring lines) and in the left ventricle in four. In 
two patients intracardiac thrombus developed while 
protamine was being given to reverse systemic hep- 
arinization immediately after cardiopulmonary b - 
pass. Both were being monitored with transesopha- 
geal echocardiography at the time of clot formation. 
In one patient the entire ECMO circuit became 
clotted and he died in the operating room. Four 
patients who received extracorporeal life support 
had postoperative intracardiac thrombus, first noted 
at 37.5 _+ 28.7 hours (range 6 to 72 hours). Table VI 
demonstrates the prothrombin time, partial pro- 
thrombin time, and platelet count at the time of 
postoperative thrombus identification in these four 
patients. 
Blood transfusion was common during the extra- 
corporeal life support. The amount of blood trans- 
fused during the entire hospitalization broken down 
by components i demonstrated in Table VII. No 
significant difference was noted in the amount of 
blood transfused to patients bridged to transplanta- 
tion compared with that needed by the other pa- 
tients treated only with extracorporeal life support. 
Survivai. Twelve patients died during extracor- 
poreal ife support (40%). Nine patients were trans- 
ferred to an implantable l ft ventricular assist device 
for possible heart transplantation (30%). Of these 
patients, five received hearts and were discharged 
home. Nine patients were weaned from extracorpo- 
real life support, and four were discharged home 
from the hospital. Overall, nine patients treated by 
extracorporeal life support (30%) were successfully 
discharged home. 
Statistical analysis revealed that in patients in 
whom intracardiac thrombus developed, oxygenator 
changes were more frequently required (3/6 versus 
9/24,p = 0.038), as well as red blood cell transfusion 
(38.29 versus 58.00, p = 0.028). When placed into a 
univariate logistic regression analysis model, the 
number of oxygenators changed was too small for 
convergence, but the greater the number of red 
blood cells transfused the greater the likelihood of 
intracardiac lot formation. Variables associated 
with the ability to be weaned from ECMO included 
male sex (p = 0.013). Interestingly, on univariate 
logistic regression analysis the presence of a dilated 
left ventricle was a negative predictor of ability to be 
weaned from ECMO (p = 0.032) and male sex a 
positive predictor of ability to be weaned (p = 
0.011). Variables associated with hospital deaths 
included longer bypass time (p = 0.045) in patients 
having postcardiotomy cardiogenic shock, length of 
time supported by ECMO (p = 0.008), and number 
of packed red blood cells transfused (p = 0.045). 
The need for oxygenator change was also associated 
with death (p = 0.049). When placed into a univa- 
riate logistic regression analysis, none proved to be 
predictors of death. 
Table III. Important patient characteristics 
ECMO Blood Weaned or 
Patient placernent Cannula IABP TEE Heparin transfusions, HeartMate 
No. (hr) location use findings use PRBG (U) Device failures LVAD Survival Cause of death 
1 OR RA to Ao Yes Dilated LV 
2 OR Femoral Yes Dilated LV 
3 OR Femoral Yes Dilated LV 
4 ICU (16) Femoral Yes Dilated LV/ 
postop, contrast 
5 OR Femoral No 
6 OR Femoral Yes Dilated LV/ 
clot 
7 OR RA to Ao Yes 
8 OR FV to Ao Yes 
9 OR Femoral Yes 
10 ICU (77) Femoral No 
11 ICU (322) Femoral No 
12 ICU (48) Femoral Yes 
13 ICU (14) Femoral No 
14 OR Femoral Yes 
15 Cath Lab Femoral Yes 
16 Cath Lab Femoral No 
17 OR RA to Ao No 
18 OR Femoral Yes 
19 1CU Femoral Yes 
20 OR Femoral Yes 
21 ICU Femoral Yes 
22 OR Femoral Yes 
23 Cath Lab Femoral Yes 
24 ICU (12) Femoral No 
Sponta- 
r leOUS 
contrast 
Dilated LV/ 
clot 
Clot 
Dilated LV/ 
clot 
Dilated LV 
Dilated LV 
Dilated LV 
Dilated LV 
Dilated LV 
Sponta- 
r leoLls  
contrast 
Sponta- 
ncous  
contrast 
Dilated LV/ 
sponta- 
neous 
contrast 
Clot 
No 49 No Yes Yes 
No 44 No HeartMate Yes 
No 21 No Yes Yes 
No 43 No HeartMate Yes 
No 40 No No No 
No 67 No No No 
No 39 No No 
No 43 Oxygenator No 
change 
Cardiac 
Endocarditis 
No Cardiac 
No Multiorgan failure 
No 41 No HeartMate No 
No 73 Oxygenator No No 
change × 1 
No 16 Oxygenator Yes Yes 
change ×2 
No 51 Oxygenator No No 
change ×2, 
pump-head 
change 
No 97 Oxygenator Yes No 
change × 1, 
pump clot 
No 11 Oxygenator Yes No 
change ×2 
No 26 Oxygenator No No 
change ×3 
Yes 22 Pump-head No No 
change 
Yes 10 No Yes Yes 
No 79 No No No 
No 58 Oxygenator HeartMate No 
change ×2 
No 32 No HeartMate Yes 
Yes 50 No HeartMate Yes 
Cardiac 
Multiorgan failure 
Cardiac 
Cardiac 
Cardiac 
Multiorgan failure 
ARDS 
Multiorgan failure 
Multiorgan failure 
No 05 Oxygenator No No Cardiac 
change ×2 
No 66 No HeartMate No Multiorgan failure 
No 32 No No No Rupture hypogastric 
artery aneurysm 
25 ICU (29) Femoral Yes Contrast No 3i Oxygenator Yes No Cardiac 
change ×2 
26 Cath Lab Femoral Yes Contrast No 40 No HeartMate No Multiorgan failure 
27 Cath Lab Femoral Yes No 12 No HeartMate Yes 
28 OR RA to Ao Yes No 45 No Yes No Multiorgan failure 
29 ICU (48) Femoral Yes Dilated LV Yes 26 Oxygenator No No Cardiac 
change x1 
30 OR RA to Ao Yes Dilated LV/ No 44 Oxygenator Yes No Multiorgan failure 
contrast/ change x2, 
clot pump clot 
ECMO, Extracorporeal membrane oxygenator;/ABP, intraaortic balloon pump; TEE, transesophageal echocardiography; PRBC, packed red blood cells; 
LVAD, left ventricular ssist device; OR, operating room; ICU, intensive care unit; Cath Lab, catheterization laboratory; RA, right atrium; Ao, aorta; FV, 
femoral vein; LV, left ventricle; ARDS, adult respiratory distress syndrome. 
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Table IV. Complications ofextracorporeal life 
support 
Patients 
No. % 
Limb ischemia (discoloration, 21 70 
coolness, or loss of sensation) 
Dialysis 14 47 
Oxygenator failure 13 43 
Bleeding necessitating reexploration 12 40 
Infection 9 30 
Bacteremia 6 
Pneumonia 2 
Mediastinitis 1 
Pump head change 4 13 
Cerebral vascular accident 3 10 
Continuous venoveno ultrafiltration 3 10 
Table V. Transesophageal chocardiographic 
findings during extracorporeal life support 
Patients 
No. % 
Dilated left ventricle 15 50 
Sluggish intracardiac blood flow 8 27 
lntracardiac thrornbus 6 20 
Microbubbles coming from arterial cannula 2 7 
Discussion 
The first successful use of a ventricular assist 
device for postcardiotomy cardiogenic shock was 
reported by Spencer and associates 1° in 1965. In 
1979 we began a program using centrifugal pumps 
for patients with postcardiotomy cardiogenic shock. 
During the 12-year period from August 1979 to 
August 1991 a total of 91 patients were supported 
with such devices. 11 Although we were able to wean 
62% of our patients ffom ventricular assist device 
support, only 25.3% were discharged from the hos- 
pital. Moreover, the major morbidity was due to 
bleeding (87.3%), as well as renal failure (46.8%), 
which eventually led us to look at alternative modes 
of ventricular support associated with less bleeding 
and multiorgan failure. During this time there was a 
resurgence in the use of ECMO for adults having 
cardiogenic shock. In 1984 Pennington and col- 
leagues 12 reported on a group of 14 patients with 
postcardiotomy cardiogenic shock who were sup- 
ported with venoarterial extracorporeal life support 
for almost 60 hours. Only three patients were 
weaned, but all were young and were not bleeding 
when the life support system was inserted. The other 
patients in this series had significant problems with 
Table VI. Clotting parameters atthe time of 
clot detection 
Prothrombin time 
(sec) 
Partial thromboplastin 
time (sec) 
Platelet count 
15.9 _+ 2.8 (range 12.7-19.6) 
39.7 + 14.8 (range 30.3-61.5) 
85.3 ± 43.3 100,000 (fange 60-150,000) 
Table VII. Average blood products transfused 
per patient 
Packed red blood cells (U) 
Fresh frozen plasma (U) 
Platelets (U) 
Cryoprecipitate (U) 
42.4 +_ 21.0 (fange 10-97) 
7.9 +- 11.0 (range 0-5) 
55.3 +- 39.2 (range 12-192) 
46.3 ± 37.2 (range 0-144) 
bleeding hemolysis and progressive multisystem or- 
gan failure. In 1991, the Carmeda Corporation in 
Stockholm, Sweden, released aheparin-coating pro- 
cess that was used to produce an antithrombogenic 
surface. 13 This process was applied to extracorpo- 
real tubing in addition to the hollow-fiber micro- 
porous oxygenator surface. 4 Subsequent clinical re- 
ports demonstrated reduced fibrin deposition, 
granulocyte activation, 14 and complement activa- 
tionJ 5 The heparin-bonded surface appeared to 
protect against he inflammatory response of pro- 
longed extracorporeal support and reduced the 
amount of bleeding when little or no systemic 
heparinization was used. 6'/6 Bindsler,16 Mottaghy,6 
and their coworkers reported excellent hemody- 
namic support with minimal postoperative blood 
loss using a heparin-coated (Carmeda) extracorpo- 
real circuit without systemic heparinization i exper- 
imental animals for up to 5 days. Clinically, Magov- 
ern and colleagues 3 reported excellent results in 
patients with postcardiotomy cardiogenic shock us- 
ing a heparin-coated ECMO circuit and no systemic 
heparinization. They were unable to demonstrate 
any evidence for disseminated intervascular coagu- 
lation, and thrombin was not measured. Data were 
unavailable as to whether patients had evidence of 
stagnant intracardiac blood, left ventricular disten- 
tion, or intracardiac lot formation. The 20% inci- 
dence of intracardiac thrombus formation in our 
series detected by transesophageal echocardiogra- 
phy, in patients treated with heparin-coated ECMO 
circuits without routine systemic heparinization, 
represents a major limitation to this technique. 
Moreover, we have probably underestimated the 
risk of intracardiac thrombus formation because 
some thrombi could have been below the resolution 
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of transesophageal echocardiography. As an exam- 
ple, in orte of our patients an old intracardiac 
thrombus was noted at the time of left ventricular 
assist device placement as a bridge to heart trans- 
plantation. This thrombus had not been detected on 
transesophageal echocardiography and, if counted, 
would actually increase the incidence of intracardiac 
thrombus in our report to 23.3%. Moreover, it is 
unlikely that clot detected on transesophageal cho- 
cardiography was misdiagnosed asintracardiac throm- 
bus. In all sbc patients having intracardiac thrombus, 
the clotting was documented on pathologic specimens. 
In three patients the thrombus was confirmed at a 
second operation; in another one patient the entire 
ECMO circuit became clotted, and the patient died; in 
another patient clot was removed at the time of left 
ventricular a,~sist device implantation as a bridge to 
cardiac transplantation; and in the sixth patient hrom- 
bus was confirmed at autopsy. 
Thrombus formation in patients supported with 
heparin-coated ECMO circuits without systemic hep- 
arinization is not a new finding. Magovern and 
coworkers 3 reported that thrombus developed in 
three of 21 patients (14.2%) in whom this support 
strategy was used. Two patients had clot in a cannula 
and one had a cerebrovascular ccident and was 
retrospectively noted to have an intraeardiac throm- 
bus after the ECMO system had been removed. 
Transesophageal echocardiography as also been 
shown to be sensitive in detecting thrombus forma- 
tion in patients in whom a heparin-coated ECMO 
circuit and reduced systemic heparinization were 
used. Cheung and coworkers s reported on a patient 
in whom intracardiac thrombus developed after 
mitral valve replacement for which the systemic 
heparin dose was 1 mg/kg during the bypass run. A 
low concentration of systemic heparin was used 
because the patient had had a hemorrhagic brain 
infarction and required an urgent operation. Post- 
bypass intraoperative transesophageal chocardiog- 
raphy before protamine administration demon- 
strated that a thrombus had formed on the 
bioprosthesis. Emergency reoperation was per- 
formed and the clot was removed. 
Several factors may be responsible for the forma- 
tion of intracardiac thrombi. The abnormal albeit 
heparin-coated surface of the extracorporeal circuit 
may have contributed significantly. Blood contact 
with abnormal surfaces, even in the presence of 
heparin, causes activation of factor XII (Hageman 
factor), 17 which initiates a body defense reaction 
resulting in thrombin formation in an effort to 
prevent bleeding. Hageman factor activates factor 
X, which is the gateway to the common coagulation 
pathway producing thrombin. Heparin works by 
neutralizing thrombin formation largely after the 
clot is formed, not before. In addition to blood being 
exposed to abnormal surfaces, stagnant intracardiac 
blood flow may also have contributed to thrombus 
formation. With decompression f the heart during 
full extracorporeal life support, stagnant blood flow 
was frequently documented on transesophageal 
echocardiographic s ans. Although decompressing 
the failing heart in an effort to diminish myocardial 
oxygen demand by decreasing left ventricular end- 
diastolic pressure is theoretically beneficial, this 
practice may actually promote clot formation. The 
increased afterload inherent o ECMO circuits com- 
pounds this problem by inhibiting blood from exiting 
the heart. Use of IABP has been advocated as a 
method of decreasing afterload in these patients and 
thereby hastening myocardial recovery. 9 Unfortu- 
nately, the IABP represents another abnormal in- 
travascular foreign body, which may further stimu- 
late the coagulation system. It is unclear whether 
selective left ventricular decompression would have 
prevented intracardiac clot or improved myocardial 
recovery. Even when the left ventrMe was able to 
eject blood, as demonstrated bypulsatile blood flow 
on an arterial pressure monitoring trace, intracar- 
diac thrombus was still able to form in several of our 
patients. Therefore, intracardiac blood flow is not 
the only answer to preventing intracardiac lot 
formation. Furthermore, heparin boluses given at 
times of decreased blood flow, such as during wean- 
ing or oxygenator changes, were inadequate to 
prevent intracardiac lot formation; therefore, sys- 
temic heparinization is probably required for the 
duration of support, preferably after massive bleed- 
ing has subsided. 
Giving protamine at the conclusion of cardiopul- 
monary bypass to reverse heparin after the life 
support system had been implemented may also 
have promoted thrombin generation, von Segesser 
and associates » recently demonstrated that reversing 
systemic heparinization with protamine in animals 
supported by a heparin-coated ECMO circuit mark- 
edly increased fibrin formation within the circuit and 
promoted platelet and red blood cell deposition. 
Protamine administration effectively neutralized the 
heparin surface coating. This finding has also been 
shown in in vitro experiments with toluidine blue. 
Artificial surfaces with heparin surface coating are 
stained readily with toluidine blue. (This test is 
8 5 0 Muehrcke t aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1995 
routinely used for qualitative screening of heparin- 
coated surfaces in the development of manufactur- 
ing techniques for heparin-coated evices). If a 
heparin-coated polyvinylchloride tubing segment is 
dipped on one side in protamine solution and 
thereafter stained with toluidine blue, the part ex- 
posed to protamine does not fix the staining agent. 
The protamine deactivates surface-bound heparin. 
It is interesting that thrombus only developed in our 
patients having postcardiotomy cardiogenic shock 
after protamine was given and in no patients receiv- 
ing systemic heparin. The patients in Magovern's 
series 3in whom clot developed also had been given 
protamine to reverse systemic heparinization after 
heart operations. Therefore, no protamine should 
be given during peffusion with heparin-coated 
equipment. Although protamine is useful after stan- 
dard cardiopulmonary bypass, it can be avoided. 
Heparin spontaneously degrades with time, and 
fresh-frozen plasma and coagulation factors can be 
given to avoid protamine administration. More re- 
cently, an extracorporeal heparin reversal device in 
which the hollow fibers are immobilized with poly- 
L-lysine has been developed, 18which obviates the 
need for protamine. Had we not reversed systemic 
heparin with protamine in patients having postcar- 
diotomy cardiogenic shock, the incidence of throm- 
bus formation may have been lower. However, if 
protamine does neutralize the heparin coating on 
extracorporeal tubing, it remains to be seen whether 
systemic heparinization is needed if protamine isnot 
used. 
Our study points out the high rate of complica- 
tions associated with extracorporeal life support 
systems for which peripheral cannulation without 
systemic heparinization is used. The most frequent 
complication we observed was limb ischemia, and 
clearly better ways of peripheral cannulation are 
needed. The reported advantages of percutaneous 
peripheral cannulation include the ease of initiating 
extracorporeal life support in emergency situations. 
Peripheral cannulation also allows for chest closure, 
and no resternotomy is required to remove the 
cannula. Methods of dealing with limb ischemia in 
patients cannulated peripherally have included sep- 
arate proximal and distal femoral artery catheters to 
perfuse the patient as well as the limb distally, using 
right-angled high-flow arterial cannulas to permit 
bidirectional arterial cannula flow. 19 More recently, 
we have began to use distal leg perfusion and have 
found this to significantly reduce the incidence of leg 
ischemia. 
Moreover, the incidence of complications associ- 
ated with the use of ECMO is similar to the rate of 
complications with centrifugal pumps at our institu- 
tion. It is difficult, however, to determine if most 
complications area  result of the treatment rather 
than a complication of the disease state. Nonethe- 
less, renal failure necessitating dialysis or continu- 
ous venoveno ultrafiltration was similar to the 
43.2% incidence of patients requiring hemodialysis 
and the 13.5% incidence of patients requiring con- 
tinuous ultrafiltration in out cohort of 91 patients 
supported with a centrifugal mechanical ventricular 
support system reported in 1992. Moreover, the 
transfusion requirements for patients managed with 
extracorporeal life support with heparin-bound ex- 
tracorporeal circuits not maintained on systemic 
heparinization was not different from the 87.3% of 
patients requiring massive transfusion supported 
with the centrifugal mechanical ventricular support 
devices with systemic heparinization reported in out 
earlier study in 1992.11 Similarly, the incidence of 
cerebral vascular accidents and infections was com- 
parable. New complieations unique to extracorpo- 
real life support, however, were recognized, as de- 
scribed earlier. 
The need to change the oxygenator occurred in 
43%. Thirteen percent of our patients required 
pump-head changes, half of the time because of clot 
formation in the pump head. Had heparinization 
been used during the extracorporeal tun, this may 
have reduced the number of pump-head changes 
required; however, whether it would have influ- 
enced the rate of oxygenator failure is unclear. 
Clearly, hollow-fiber oxygenators fail more fre- 
quently if clots form in the oxygenator. Intracardiac 
thrombus was more frequently seen in patients 
requiring oxygenator changes. Orte limitation of our 
study was that the patients who underwent oxygen- 
ator change did not have their oxygenators exam- 
ined microscopically for thrombus formation. Add- 
ing systemic heparinization potentially could have 
reduced the need for oxygenator ehanges and pump- 
head changes. Another limitation of out study is that 
the two types of circulatory support were not com- 
pared during the same trial period in comparable 
patients or in a prospective fashion. Nonetheless, 
the incidence of complications and survival rates 
appear to be similar. 
In conelusion, the strategy of using heparin- 
coated extracorporeal life support systems without 
systemic heparinization is not without risk. Intracar- 
diac thrombus formation and perhaps an inereased 
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incidence of oxygenator failure appears to limit this 
strategy. Until clinical studies document the safe use 
of these circuits without systemic heparinization, 
especially when protamine has been avoided, sys- 
temic heparinization should be used. Use of heparin 
throughout the period of support appears justified 
and protamine should not be given. Furthermore, 
the use of peripheral cannulation in an effort to 
reduce mediastinal blood loss after postcardiotomy 
cardiogenic shock must also be questioned, and 
distal leg perfusion with a separate catheter may 
help prevent leg ischemia. Transfusion require- 
ments were similar to those in historical reports of 
patients cannulated via the mediastinum with cen- 
trifugal pumps. Although we were not able to find 
an advantage of extracorporeal life support using a 
heparin-coated ECMO circuit compared with our 
historical results using centrifugal pumps and sys- 
temic heparinization, many of the problems unique 
to ECMO ~upport may be surmountable. 
We thank Judith A. Borsh, RN, for her help with chart 
reviews and Shelly K. Sapp, MS, for statistical analysis. 
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